MAPT and amyloidosis: However, acknowledging the contradictory results from post-mortem26 and PET studies61 alongside the non-specific nature of GFAP,62,63 it is plausible that GFAP levels may reflect different pathologies depending on the stage of the disease: amyloid pathology at the early stages and tau pathology at the later stages.